ArticleJournal of nanobiotechnology2026
Microneedle-delivered ROS-adaptive asiatic acid nanoparticles promote scarless repair via remodeling the pathological microenvironment.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hydrogel microneedles functioning in pathological surroundings: where soft materials overcome hard scars.Materials today. Bio · 2026Review
- Engineering Multi-Scale Transdermal Delivery Systems for Atopic Dermatitis: Emerging Insights from the Gut-Skin Axis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hypertrophic scar (HS) is a pathologic fibrotic disease caused by aberrant wound healing following severe skin injury. Despite advances in clinical treatments, the therapeutic outcomes remain suboptimal, mainly due to inadequate penetration through the thickened stratum corneum barrier and insufficient site-specific drug delivery within the lesional tissue. To address these limitations, we developed a hyaluronic acid-based dissolving microneedle array loaded with reactive oxygen species (ROS)-responsive asiatic acid nanoparticles (AA/PTP MN). This advanced platform facilitates direct intradermal delivery of therapeutic agents by penetrating the stratum corneum. Upon dissolution in the scar tissue, the released AA/PTP nanoparticles respond to the elevated ROS levels, enabling precise and sustained release of asiatic acid (AA) to actively remodel the pathological microenvironment. This innovative nano-micro platform exhibited excellent ROS sensitivity, robust mechanical properties, and good biocompatibility. In vitro experiments revealed that AA/PTP can specifically inhibited the proliferation of hypertrophic scar fibroblasts and reduced macrophage migration. In the rabbit ear HS model, AA/PTP MN treatment effectively remodeled the pathological HS microenvironment, as evidenced by significantly reduced scar thickness, normalized collagen architecture, and marked inhibition of skin fibrosis. RNA sequencing analysis confirmed that this therapeutic effect was achieved through multi-faceted regulation of the scar microenvironment: inhibiting fibroblast and keratinocyte proliferation, attenuating inflammation, and reducing excessive collagen deposition. In summary, this microneedle-based strategy of microenvironment-specific drug release represents a promising and effective therapeutic avenue for achieving scarless regeneration in hypertrophic scars.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.